USP43 promotes gemcitabine resistance in bladder cancer by stabilizing E2F1 to regulate cholesterol homeostasis
Gemcitabine (GEM) resistance remains a critical barrier in the treatment of bladder cancer (BLCA). Based on the observation that metabolic reprogramming drives chemoresistance, we identified USP43 as a promoter of GEM resistance via an E2F1-driven mechanism that modulates cholesterol metabolism.